| A-86929 | |
|---|---|
|
9,10-Dihydroxy-2-propyl-4,5,5a(R),6,7,11b(S)-hexahydrobenzo[f]thieno[2,3-c]quinoline |
|
| Identifiers | |
| CAS number | 166591-11-3 |
| PubChem | 9841398 |
| ChemSpider | 8017113 |
| ChEMBL | CHEMBL28338 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C18H21NO2S |
| Molar mass | 315.429 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
A-86929 is a synthetic compound that acts as a selective dopamine receptor D1 agonist.[1][2] It was developed as a possible treatment for Parkinson's disease,[3] as well as for other applications such as treatment of cocaine addiction,[4][5] but while it had reasonable efficacy in humans it also caused dyskinesias and has not been continued.[6][7] It has mainly been used as its diacetate ester prodrug adrogolide (ABT-431), which has better bioavailability.[8][9]
| This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)